Swiss pharmaceutical company Roche has announced that U.S. health regulators have agreed to grant priority review to its Tecentriq immunotherapy treatment for a type of bladder cancer. In a statement, the drug company said that the U.S. Food and Drug Administration has accepted its Biologics License Application, or BLA, and agreed to priority-review the treatment. Tecentriq Tecentriq (atezolizumab)...